Table 2 Classification results from multilevel PLS-DA and PLS-DA
From: Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
Class. model | No. of LVs | Variance X/Y (%) | Sensitivity/ Specificity (%) | Class. accuracy (%) | Permutation p-value | ||||
|---|---|---|---|---|---|---|---|---|---|
Paired data | All samples | Control vs Treatment | (n = 65p) | Multilevel PLS-DA | 2 | 58.9/50.9 | 87.9/87.9 | 87.9 | < 0.001 |
Partial response | Control vs Treatment | (n = 37p) | Multilevel PLS-DA | 2 | 55.7/61.7 | 80.0/80.0 | 80.0 | < 0.001 | |
Stable disease | Control vs Treatment | (n = 28p) | Multilevel PLS-DA | 2 | 63.2/61.3 | 88.7/88.7 | 88.7 | < 0.001 | |
Survivors | Control vs Treatment | (n = 44p) | Multilevel PLS-DA | 2 | 60.0/50.5 | 83.0/83.0 | 83.0 | < 0.001 | |
Non-survivors | Control vs Treatment | (n = 19p) | Multilevel PLS-DA | 2 | 70.6/63.9 | 82.5/82.5 | 82.5 | 0.006 | |
Unpaired data | All samples | Pre- vs Post-treatment | (n = 65p) | PLD-DA | 2 | 50.3/29.2 | 80.7/57.1 | 68.9 | < 0.001 |
Pre-treatment | Partial response vs Stable disease | (n = 48) (n = 32) | PLS-DA | 2 | 51.5/19.3 | 56.7/60.2 | 58.4 | 0.231 | |
Post-treatment | Partial response vs Stable disease | (n = 41) (n = 29) | PLS-DA | NaN | - | - | - | - | |
Pre-treatment | Survivors vs Non-survivors | (n = 57) (n = 20) | PLS-DA | NaN | - | - | - | - | |
Post-treatment | Survivors vs Non-survivors | (n = 47) (n = 21) | PLS-DA | 3 | 62.8/32.1 | 58.4/75.3 | 70.1 | 0.009 | |
Post-treatment | Epirubicin vs Paclitaxel | (n = 29) (n = 23) | PLS-DA | 2 | 45.7/26.8 | 45.0/48.3 | 46.5 | 0.245 |